Summary

The research team projects that the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market size will grow from XXX in 2025 to XXX by 2030, at an estimated CAGR of XX. The base year considered for the study is 2024, and the market size is projected from 2025 to 2030.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:
Sarepta Therapeutics
Inc
NS Pharma
Inc.
Nippon Shinyaku
Dyne
Avidity Biosciences

By Type
DMD exon 51 Based
DMD exon 53 Based
DMD exon 45 Based
Other

By Application
Hospital
Clinic

By Regions/Countries:
North America
United States
Canada
Mexico

East Asia
China
Japan
South Korea

Europe
Germany
United Kingdom
France
Italy
Russia
Spain
Netherlands
Switzerland
Poland

South Asia
India
Pakistan
Bangladesh

Southeast Asia
Indonesia
Thailand
Singapore
Malaysia
Philippines
Vietnam
Myanmar

Middle East
Turkey
Saudi Arabia
Iran
United Arab Emirates
Israel
Iraq
Qatar
Kuwait
Oman

Africa
Nigeria
South Africa
Egypt
Algeria
Morocoo

Oceania
Australia
New Zealand

South America
Brazil
Argentina
Colombia
Chile
Venezuela
Peru
Puerto Rico
Ecuador

Rest of the World
Kazakhstan

Points Covered in The Report
The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.
The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.
Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.
The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of PMO (Phosphorodiamidate Morpholino Oligomers) Drug 2019-2024, and development forecast 2025-2030 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2019-2024 & Sales by Product Types.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2025-2030. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.
Market Analysis by Product Type: The report covers majority Product Types in the PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry, including its product specifcations by each key player, volume, sales by Volume and Value (M USD).
Markat Analysis by Application Type: Based on the PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market in 2024. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Type: 2025 VS 2030
1.4.2 DMD exon 51 Based
1.4.3 DMD exon 53 Based
1.4.4 DMD exon 45 Based
1.4.5 Other
1.5 Market by Application
1.5.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application: 2025-2030
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market
1.8.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Status and Outlook (2019-2030)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
1.9 Global Market Growth Prospects
1.9.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Estimates and Forecasts (2019-2030)
1.9.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity Estimates and Forecasts (2019-2030)
1.9.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Estimates and Forecasts (2019-2030)
2 Manufacturing Cost Structure Analysis
2.1 Raw Material
2.2 Manufacturing Cost Structure Analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug
2.3 Manufacturing Process Analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug
2.4 Industry Chain Structure of PMO (Phosphorodiamidate Morpholino Oligomers) Drug
3 Development and Manufacturing Plants Analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug
3.1 Top Manufacturers Headquarters, Rank by PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Manufacturing Plants Distribution and Commercial Production Date
4 Market Competition by Manufacturers
4.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity Market Share by Manufacturers (2019-2024)
4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Manufacturers (2019-2024)
4.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Average Price by Manufacturers (2019-2024)
4.4 Manufacturers PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Sites, Area Served, Product Type
5 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Regional Market Analysis
5.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production by Regions
5.1.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production by Regions (2019-2024)
5.1.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Regions
5.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Consumption by Regions
5.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.3.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.3.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import and Export
5.4 East Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.4.1 East Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.4.2 East Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.4.3 Key Manufacturers in East Asia
5.4.4 East Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
5.5 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.5.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.5.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.5.3 Key Manufacturers in Europe
5.5.4 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
5.6 South Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.6.1 South Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.6.2 South Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.6.3 Key Manufacturers in South Asia
5.6.4 South Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
5.7 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.7.1 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.7.2 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
5.8 Middle East PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.8.1 Middle East PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.8.2 Middle East PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.8.3 Key Manufacturers in Middle East
5.8.4 Middle East PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
5.9 Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.9.1 Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.9.2 Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.9.3 Key Manufacturers in Africa
5.9.4 Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
5.10 Oceania PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.10.1 Oceania PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.10.2 Oceania PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.10.3 Key Manufacturers in Oceania
5.10.4 Oceania PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
5.11 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis
5.11.1 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production
5.11.2 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue
5.11.3 Key Manufacturers in South America
5.11.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Import & Export
6 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Market by Type (2019-2030)
6.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size by Type (2019-2024)
6.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Type (2025-2030)
7 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Consumption Market by Application(2019-2030)
7.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size by Application (2019-2024)
7.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Application (2025-2030)
8 Company Profiles and Key Figures in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business
8.1 Sarepta Therapeutics
8.1.1 Sarepta Therapeutics Company Profile
8.1.2 Sarepta Therapeutics PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Specification
8.1.3 Sarepta Therapeutics PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.2 Inc
8.2.1 Inc Company Profile
8.2.2 Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Specification
8.2.3 Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.3 NS Pharma
8.3.1 NS Pharma Company Profile
8.3.2 NS Pharma PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Specification
8.3.3 NS Pharma PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.4 Inc.
8.4.1 Inc. Company Profile
8.4.2 Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Specification
8.4.3 Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.5 Nippon Shinyaku
8.5.1 Nippon Shinyaku Company Profile
8.5.2 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Specification
8.5.3 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.6 Dyne
8.6.1 Dyne Company Profile
8.6.2 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Specification
8.6.3 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.7 Avidity Biosciences
8.7.1 Avidity Biosciences Company Profile
8.7.2 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Specification
8.7.3 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production Capacity, Revenue, Price and Gross Margin (2019-2024)
9 Production and Supply Forecast
9.1 Global Forecasted Production of PMO (Phosphorodiamidate Morpholino Oligomers) Drug (2025-2030)
9.2 Global Forecasted Revenue of PMO (Phosphorodiamidate Morpholino Oligomers) Drug (2025-2030)
9.3 Global Forecasted Price of PMO (Phosphorodiamidate Morpholino Oligomers) Drug (2019-2030)
9.4 Global Forecasted Production of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Region (2025-2030)
9.4.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.2 East Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.4 South Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.5 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.6 Middle East PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.7 Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.8 Oceania PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.9 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.4.10 Rest of the World PMO (Phosphorodiamidate Morpholino Oligomers) Drug Production, Revenue Forecast (2025-2030)
9.5 Forecast by Type and by Application (2025-2030)
9.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2025-2030)
9.5.2 Global Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Application (2025-2030)
10 Consumption and Demand Forecast
10.1 North America Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.2 East Asia Market Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.3 Europe Market Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Countriy
10.4 South Asia Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.5 Southeast Asia Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.6 Middle East Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.7 Africa Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.8 Oceania Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.9 South America Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
10.10 Rest of the world Forecasted Consumption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country
11 Marketing Channel, Distributors and Customers
11.1 Marketing Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
12 Market Dynamics
12.1 Market Trends
12.2 Opportunities and Drivers
12.3 Challenges
12.4 Porter's Five Forces Analysis
13 Conclusion
14 Appendix
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer